APA (7th ed.) Citation

AS, P., MJ, C., HC, H., W, S., SKR, S., H, L., . . . A, W. (2026). Clinical Laboratory Parameters in Adolescents with Moderate-to-Severe Atopic Dermatitis Treated with Tralokinumab Up to Week 52 in the Phase 3 ECZTRA 6 Trial. Dermatology and therapy, 16(6), 3037. https://doi.org/10.1007/s13555-026-01745-7

Chicago Style (17th ed.) Citation

AS, Paller, Cork MJ, Hong HC, Soong W, Schneider SKR, Lo H, Vinther F, Thøgersen P, and Wollenberg A. "Clinical Laboratory Parameters in Adolescents with Moderate-to-Severe Atopic Dermatitis Treated with Tralokinumab Up to Week 52 in the Phase 3 ECZTRA 6 Trial." Dermatology and Therapy 16, no. 6 (2026): 3037. https://doi.org/10.1007/s13555-026-01745-7.

MLA (9th ed.) Citation

AS, Paller, et al. "Clinical Laboratory Parameters in Adolescents with Moderate-to-Severe Atopic Dermatitis Treated with Tralokinumab Up to Week 52 in the Phase 3 ECZTRA 6 Trial." Dermatology and Therapy, vol. 16, no. 6, 2026, p. 3037, https://doi.org/10.1007/s13555-026-01745-7.